Dr. John Neilan

Dr. John Neilan serves as Science Lead within the Science Technology Acquisition Division (70RSAT) of the Department of Homeland Security’s Office of Procurement Operations, where he provides technical oversight and strategic direction for the acquisition of advanced scientific and engineering capabilities critical to national security. His role bridges scientific innovation with federal procurement, ensuring that R&D initiatives in life sciences, biotechnology, and pharmaceutical development align with operational requirements for homeland defense systems. Dr. Neilan specializes in complex, high-risk acquisitions involving novel detection technologies, biosecurity countermeasures, and next-generation medical countermeasures, often coordinating with federal laboratories and industry partners to translate laboratory breakthroughs into deployable capabilities. His primary contractor relationships center on MICROSOFT CORPORATION, with whom he collaborates on integrated scientific platforms, data analytics systems, and secure cloud infrastructure supporting biomedical research and threat modeling. While Microsoft is the dominant partner, Dr. Neilan also engages with specialized biotech and pharmaceutical firms to procure proprietary reagents, diagnostic platforms, and bioinformatics tools. His procurement approach emphasizes performance-based outcomes, technical validation, and long-term system interoperability over commoditized purchases. Dr. Neilan’s contracting portfolio reflects no set-aside preferences, with 100% of awards issued under full and open competition. This reflects a mission-driven focus on accessing the most technically capable providers, regardless of socioeconomic status, prioritizing scientific rigor and rapid deployment over socioeconomic targets. His procurement activity is concentrated in NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 541714 (Research and Development in Biotechnology), underscoring his expertise in procuring mRNA-based therapeutics, biosensors, lab-developed tests, and engineered biological agents for threat detection and medical countermeasure development. He operates at the intersection of regulatory science, FDA-aligned development pathways, and defense acquisition frameworks, ensuring compliance with both public health and national security standards.